Australia - englanti - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - etacrynic acid -

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - etacrynic acid 50mg - tablet - 50 mg - active: etacrynic acid 50mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch purified talc

Kanada - englanti - Health Canada

sterimax inc - ethacrynic acid (ethacrynate sodium) - powder for solution - 50mg - ethacrynic acid (ethacrynate sodium) 50mg - loop diuretics

Kanada - englanti - Health Canada

endo par innovation company, llc - ethacrynic acid (ethacrynate sodium) - powder for solution - 50mg - ethacrynic acid (ethacrynate sodium) 50mg - loop diuretics

Kanada - englanti - Health Canada

bausch health, canada inc. - ethacrynic acid (ethacrynate sodium) - powder for solution - 50mg - ethacrynic acid (ethacrynate sodium) 50mg - loop diuretics

Kanada - englanti - Health Canada

bausch health, canada inc. - ethacrynic acid - tablet - 25mg - ethacrynic acid 25mg - loop diuretics

Kanada - englanti - Health Canada

vpi pharmaceuticals inc - ethacrynic acid (ethacrynate sodium) - powder for solution - 50mg - ethacrynic acid (ethacrynate sodium) 50mg - loop diuretics

Australia - englanti - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - vancomycin hydrochloride, quantity: 952 mg (equivalent: vancomycin, qty 1000000 iu) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - vancomycin juno is indicated in potentially life-threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin juno is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin juno is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g. e. faecalis), vancomycin juno is effective only in combination with an aminoglycoside. vancomycin juno is effective for the treatment of diphtheroid endocarditis. vancomycin juno is used in combination with rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin juno has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia, and soft tissue infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin juno.,vancomycin juno should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis produced by c. difficile. parenteral administration of vancomycin juno alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis

Australia - englanti - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - vancomycin hydrochloride, quantity: 476 mg (equivalent: vancomycin, qty 500000 iu) - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin juno is indicated in potentially life-threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin juno is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin juno is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g. e. faecalis), vancomycin juno is effective only in combination with an aminoglycoside. vancomycin juno is effective for the treatment of diphtheroid endocarditis. vancomycin juno is used in combination with rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin juno has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia, and soft tissue infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin juno.,vancomycin juno should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis produced by c. difficile. parenteral administration of vancomycin juno alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 1025.2 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.